New Companies
Filter News
Found 3,006 articles
-
Accent Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $40 million Series A financing. Accent will focus on the fairly new area of epitranscriptomics.
-
Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies
5/16/2018
Eleven Biotherapeutics is rebranding itself as Sesen Bio and investors are pleased. This morning shares of Eleven are up more than 4 percent in premarket trading. -
Introducing the Launch of H1. - Solving Problems for Healthcare and Life Science Companies
5/16/2018
H1. illuminates the people and findings shaping the world of healthcare
-
The financing was led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and others.
-
Triventures, Leading Healthcare Investor, Backs Genoox in $6 Million Funding Round
5/15/2018
Genoox, today announced it closed a $6 million funding round.
-
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...
5/14/2018
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners. -
Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing
5/14/2018
Beam Therapeutics announced today that it is launching to develop precision genetic medicines
-
Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Poten...
5/11/2018
Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney's Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients. -
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
-
Chief Operating Officer Deepti Jain to Lead IngenioRx
5/10/2018
Anthem, Inc. (NYSE:ANTM) announced today that Deepti Jain will lead IngenioRx
-
Escient Pharmaceuticals launched in San Diego with a Series A financing round worth $40 million. The round was syndicated by The Column Group and 5AM Ventures, and joined by Osage University Partners.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
-
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
-
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
-
Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business
5/1/2018
Separation designed to unlock value, increase operational performance and strategic flexibility, and tailor capital structure for each business
-
Proniras Corporation launched from Accelerator Life Science Partners to treat nerve agents. The company recently received a contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) for $89.5 million.
-
Company Profile for SPECTRUM PHARMACEUTICALS
4/27/2018
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
-
Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders
4/27/2018
April 27, 2018 12:30 UTC Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders SEATTLE--( BUSINESS WIRE )-- Accelerator Life Science Partners (Accelerator), a leading life science investment and management firm, today announced that it has launched Proniras Corporation, a company developing tezampanel for the treatment of a variety of seizure disorder
-
Company Profile for Chronix Biomedical Inc.
4/27/2018
Company Profile for Chronix Biomedical Inc.